Martine Perrus-Jandrot

UMR_S1144 INSERM, 4 Avenue De L'Observatoire
Paris, 75006, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

Glycoprotein VI inhibitors: glenzocimab and EMA601 two inhibitory Fabs.

Glycoprotein VI inhibitors: glenzocimab and EMA601 two inhibitory Fabs.

Journal: European heart journal

Published: April 02, 2025

Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage.

Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage.

Journal: Journal of the American Heart Association

Published: January 17, 2025

Neutrophil extracellular traps-targeting therapy with deoxyribonuclease 1 reduces large vessel occlusion-induced downstream microvascular thromboinflammation in a rat model of stroke.

Neutrophil extracellular traps-targeting therapy with deoxyribonuclease 1 reduces large vessel occlusion-induced downstream microvascular thromboinflammation in a rat model of stroke.

Journal: Research and practice in thrombosis and haemostasis

Published: June 03, 2024

Platelets favor the outgrowth of established metastases.

Platelets favor the outgrowth of established metastases.

Journal: Nature communications

Published: September 22, 2023

Exacerbation of thromboinflammation by JAK2V617F mutation worsens the prognosis of cerebral venous sinus thrombosis.

Exacerbation of thromboinflammation by JAK2V617F mutation worsens the prognosis of cerebral venous sinus thrombosis.

Journal: Blood advances

Published: September 21, 2023

High factor VIII concentrations interfere with glycoprotein VI-mediated platelet activation in vitro.

High factor VIII concentrations interfere with glycoprotein VI-mediated platelet activation in vitro.

Journal: Journal of thrombosis and haemostasis : JTH

Published: September 15, 2023

Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial.

Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial.

Journal: The Lancet. Neurology

Published: July 17, 2023

Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial.

Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial.

Journal: PloS one

Published: June 30, 2023

Association between endometriosis, infertility and autoimmune antiplatelet glycoprotein VI antibodies in two patients.

Association between endometriosis, infertility and autoimmune antiplatelet glycoprotein VI antibodies in two patients.

Journal: Platelets

Published: June 23, 2023

Pharmacological Inhibition of Glycoprotein VI- and Integrin α2β1-Induced Thrombus Formation Modulated by the Collagen Type.

Pharmacological Inhibition of Glycoprotein VI- and Integrin α2β1-Induced Thrombus Formation Modulated by the Collagen Type.

Journal: Thrombosis and haemostasis

Published: February 22, 2023

Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.

Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.

Journal: Journal of thrombosis and haemostasis : JTH

Published: January 22, 2023

Glycoprotein VI interplay with fibrin(ogen) in thrombosis.

Glycoprotein VI interplay with fibrin(ogen) in thrombosis.

Journal: Journal of thrombosis and haemostasis : JTH

Published: August 23, 2022

Showing 1-12 of 76

Last Updated: 09/26/2026